Literature DB >> 19265149

Synergy between individual TNF-dependent functions determines granuloma performance for controlling Mycobacterium tuberculosis infection.

J Christian J Ray1, JoAnne L Flynn, Denise E Kirschner.   

Abstract

Mycobacterium tuberculosis is one of the world's most deadly human pathogens; an integrated understanding of how it successfully survives in its host is crucial to developing new treatment strategies. One notable characteristic of infection with M. tuberculosis is the formation of granulomas, aggregates of immune cells whose structure and function may reflect success or failure of the host to contain infection. One central regulator of host responses to infection, including granuloma formation, is the pleiotropic cytokine TNF-alpha. Experimental work has characterized roles for TNF in macrophage activation; regulation of apoptosis; chemokine and cytokine production; and regulation of cellular recruitment via transendothelial migration. Separating the effects of these functions is presently difficult or impossible in vivo. To this end, we applied a computational model to understand specific roles of TNF in control of tuberculosis in a single granuloma. In the model, cells are represented as discrete entities on a spatial grid responding to environmental stimuli by following programmed rules determined from published experimental studies. Simulated granulomas emerge as a result of these rules. After confirming the importance of TNF in this model, we assessed the effects of individual TNF functions. The model predicts that multiple TNF activities contribute to control of infection within the granuloma, with macrophage activation as a key effector mechanism for controlling bacterial growth. Results suggest that bacterial numbers are a strong contributing factor to granuloma structure with TNF. Finally, TNF-dependent apoptosis may reduce inflammation at the cost of impairing mycobacterial clearance.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19265149      PMCID: PMC3182770          DOI: 10.4049/jimmunol.0802297

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  67 in total

Review 1.  The interface between innate and adaptive immunity.

Authors:  Kasper Hoebe; Edith Janssen; Bruce Beutler
Journal:  Nat Immunol       Date:  2004-10       Impact factor: 25.606

2.  Activation of macrophages to inhibit proliferation of Mycobacterium tuberculosis: comparison of the effects of recombinant gamma-interferon on human monocytes and murine peritoneal macrophages.

Authors:  G A Rook; J Steele; M Ainsworth; B R Champion
Journal:  Immunology       Date:  1986-11       Impact factor: 7.397

Review 3.  A methodology for performing global uncertainty and sensitivity analysis in systems biology.

Authors:  Simeone Marino; Ian B Hogue; Christian J Ray; Denise E Kirschner
Journal:  J Theor Biol       Date:  2008-04-20       Impact factor: 2.691

4.  Identifying control mechanisms of granuloma formation during M. tuberculosis infection using an agent-based model.

Authors:  Jose L Segovia-Juarez; Suman Ganguli; Denise Kirschner
Journal:  J Theor Biol       Date:  2004-12-07       Impact factor: 2.691

5.  Mycobacterial growth inhibition by interferon-gamma-activated bone marrow macrophages and differential susceptibility among strains of Mycobacterium tuberculosis.

Authors:  I Flesch; S H Kaufmann
Journal:  J Immunol       Date:  1987-06-15       Impact factor: 5.422

Review 6.  How regulatory T cells work.

Authors:  Dario A A Vignali; Lauren W Collison; Creg J Workman
Journal:  Nat Rev Immunol       Date:  2008-07       Impact factor: 53.106

7.  Experimental epithelioid cell granulomas, tubercle formation and immunological competence: an ultrastructural analysis.

Authors:  M J Ridley; C J Heather; I Brown; D A Willoughby
Journal:  J Pathol       Date:  1983-10       Impact factor: 7.996

8.  Human tuberculous granulomas induce peripheral lymphoid follicle-like structures to orchestrate local host defence in the lung.

Authors:  Timo Ulrichs; George A Kosmiadi; Vsevolod Trusov; Sabine Jörg; Lydia Pradl; Marina Titukhina; Vladimir Mishenko; Nadya Gushina; Stefan H E Kaufmann
Journal:  J Pathol       Date:  2004-10       Impact factor: 7.996

9.  Quantitative study on the production and kinetics of mononuclear phagocytes during an acute inflammatory reaction.

Authors:  R Van Furth; M C Diesselhoff-den Dulk; H Mattie
Journal:  J Exp Med       Date:  1973-12-01       Impact factor: 14.307

10.  Foamy macrophages from tuberculous patients' granulomas constitute a nutrient-rich reservoir for M. tuberculosis persistence.

Authors:  Pascale Peyron; Julien Vaubourgeix; Yannick Poquet; Florence Levillain; Catherine Botanch; Fabienne Bardou; Mamadou Daffé; Jean-François Emile; Bruno Marchou; Pere-Joan Cardona; Chantal de Chastellier; Frédéric Altare
Journal:  PLoS Pathog       Date:  2008-11-11       Impact factor: 6.823

View more
  77 in total

1.  Macrophage polarization drives granuloma outcome during Mycobacterium tuberculosis infection.

Authors:  Simeone Marino; Nicholas A Cilfone; Joshua T Mattila; Jennifer J Linderman; JoAnne L Flynn; Denise E Kirschner
Journal:  Infect Immun       Date:  2014-11-03       Impact factor: 3.441

2.  Tumor necrosis factor neutralization results in disseminated disease in acute and latent Mycobacterium tuberculosis infection with normal granuloma structure in a cynomolgus macaque model.

Authors:  Philana Ling Lin; Amy Myers; Le'Kneitah Smith; Carolyn Bigbee; Matthew Bigbee; Carl Fuhrman; Heather Grieser; Ion Chiosea; Nikolai N Voitenek; Saverio V Capuano; Edwin Klein; JoAnne L Flynn
Journal:  Arthritis Rheum       Date:  2010-02

Review 3.  Systems biology in immunology: a computational modeling perspective.

Authors:  Ronald N Germain; Martin Meier-Schellersheim; Aleksandra Nita-Lazar; Iain D C Fraser
Journal:  Annu Rev Immunol       Date:  2011       Impact factor: 28.527

4.  In silico models of M. tuberculosis infection provide a route to new therapies.

Authors:  Jennifer J Linderman; Denise E Kirschner
Journal:  Drug Discov Today Dis Models       Date:  2014-05-09

5.  A review of computational and mathematical modeling contributions to our understanding of Mycobacterium tuberculosis within-host infection and treatment.

Authors:  Denise Kirschner; Elsje Pienaar; Simeone Marino; Jennifer J Linderman
Journal:  Curr Opin Syst Biol       Date:  2017-05-22

6.  Differential risk of tuberculosis reactivation among anti-TNF therapies is due to drug binding kinetics and permeability.

Authors:  Mohammad Fallahi-Sichani; JoAnne L Flynn; Jennifer J Linderman; Denise E Kirschner
Journal:  J Immunol       Date:  2012-02-29       Impact factor: 5.422

7.  A computational tool integrating host immunity with antibiotic dynamics to study tuberculosis treatment.

Authors:  Elsje Pienaar; Nicholas A Cilfone; Philana Ling Lin; Véronique Dartois; Joshua T Mattila; J Russell Butler; JoAnne L Flynn; Denise E Kirschner; Jennifer J Linderman
Journal:  J Theor Biol       Date:  2014-12-09       Impact factor: 2.691

8.  Identification of key processes that control tumor necrosis factor availability in a tuberculosis granuloma.

Authors:  Mohammad Fallahi-Sichani; Matthew A Schaller; Denise E Kirschner; Steven L Kunkel; Jennifer J Linderman
Journal:  PLoS Comput Biol       Date:  2010-05-06       Impact factor: 4.475

9.  Multiscale Model of Mycobacterium tuberculosis Infection Maps Metabolite and Gene Perturbations to Granuloma Sterilization Predictions.

Authors:  Elsje Pienaar; William M Matern; Jennifer J Linderman; Joel S Bader; Denise E Kirschner
Journal:  Infect Immun       Date:  2016-04-22       Impact factor: 3.441

10.  Signal regulatory protein alpha (SIRPalpha) cells in the adaptive response to ESAT-6/CFP-10 protein of tuberculous mycobacteria.

Authors:  W Ray Waters; Mitchell V Palmer; Brian J Nonnecke; Tyler C Thacker; D Mark Estes; Michelle H Larsen; William R Jacobs; Peter Andersen; James McNair; F C Minion; Konstantin P Lyashchenko; R Glyn Hewinson; H Martin Vordermeier; Randy E Sacco
Journal:  PLoS One       Date:  2009-07-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.